Leonard Bell, M.D. is the principal founder of Alexion and has been a director
of Alexion since February 1992 and the Company’s Chief Executive Officer
since January 1992. From 1991 to 1992, Dr. Bell was an Assistant Professor of
Medicine and Pathology and co-Director of the program in Vascular Biology at the
Yale University School of Medicine. From 1990 to 1992, Dr. Bell was an attending
physician at the Yale-New Haven Hospital and an Assistant Professor in the Department
of Internal Medicine at the Yale University School of Medicine. Dr. Bell was a
recipient of the Physician Scientist Award from the National Institutes of Health
and Grant-in-Aid from the American Heart Association as well as various honors
and awards from academic and professional organizations. His work has resulted
in more than 20 scientific publications and 9 patent applications. Dr. Bell received
his A.B. from Brown University and M.D. from Yale University School of Medicine.
Dr. Bell is currently an Adjunct Assistant Professor of Medicine and Pathology
at the Yale University School of Medicine.
Stephen P. Squinto, Ph.D. is a founder of Alexion and has been Executive Vice
President and Head of Research and Development since June 2007. He held the
position of Executive Vice President and Head of Research between August 2000
and June 2007. He also held the positions of Senior Vice President and Chief
Technical Officer from March 1998 to July 2000, Vice President of Research,
Molecular Sciences, from August 1994 to March 1998, Senior Director of Molecular
Sciences from July 1993 to July 1994, and Director of Molecular Development
from 1992 to July 1993. From 1989 to 1992, Dr. Squinto held various positions
at Regeneron Pharmaceuticals, Inc. including as Senior Scientist and Assistant
Head of the Discovery Group. From 1986 to 1989, Dr. Squinto was an Assistant
Professor of Biochemistry and Molecular Biology at Louisiana State University
Medical Center and an Adjunct Professor of Neuroscience at the Tulane University
Medical School. Dr. Squinto’s work has led to over 70 scientific papers
in the fields of gene regulation, growth factor biology and gene transfer. Dr.
Squinto’s work is primarily in the fields of molecular and cellular biology.
Dr. Squinto served as a Director of the Biotechnology Research and Development
Corporation, a biotechnology consortium, from 1997 to 2003. Dr. Squinto received
his B.A. in Chemistry and Ph.D. in Biochemistry and Biophysics from Loyola University
of Chicago.
David L. Hallal has been Executive Vice President and Chief Commercial Officer
since October 2012. From May 2010 and October 2012, he was Senior Vice President
, Global Commercial Operations. From November 2008 to May 2010, he was Senior
Vice President, Commercial Operations Americas, and from June 2006 until November
2008 he served as Senior Vice President, US Commercial Operations. Before joining
Alexion, Mr. Hallal served as Vice President, Sales at OSI Eyetech from April
2004 until June 2006, where he led the U.S. launch of a first-in-class anti-VEGF
therapy for age-related macular degeneration. Prior to OSI Eyetech, from 1992
until 2004, Mr. Hallal held various sales and marketing leadership positions
at Amgen and Biogen Idec, where he was involved in multiple product launches
in the areas of hematology, oncology, nephrology and immunology. Mr. Hallal
received a B.A. in Psychology from the University of New Hampshire.
Vikas Sinha, M.B.A., C.A., C.P.A. has been Executive Vice President and Chief
Financial Officer since October 2012. From September 2005 to October 2012, he
was Senior Vice President and Chief Financial Officer. From June 1994 to August
2005, Mr. Sinha held various positions with Bayer AG in the United States, Japan,
Germany, and Canada, most recently serving as Vice President and Chief Financial
Officer of Bayer Pharmaceuticals Corporation, USA from February 2001 until August
2005. At Bayer, Mr. Sinha has been responsible for financial and business risk
management, strategic planning, contracting, customer services, information
systems, and supply chain and site administration in North America. Mr. Sinha
was also a member of the Pharmaceutical Management Committee for North America.
Prior to his appointment in the United States, Mr. Sinha was Vice President
and Chief Financial Officer of Bayer Yakuhin Ltd., in Japan and Manager, Mergers
and Acquisitions with Bayer AG in Germany. He began his career at Bayer in Toronto
as part of an executive development program in the healthcare division. Prior
to Bayer, Mr. Sinha held several positions of increasing responsibilities with
ANZ Bank and Citibank in South Asia. Mr. Sinha holds a Masters of Business Administration
from the Asian Institute of Management which included an exchange program with
the University of Western Ontario (Richard Ivey School of Business). He is also
a qualified Chartered Accountant from the Institute of Chartered Accountants
of India and a Certified Public Accountant in the United States.
Clare Carmichael has been Senior Vice President and Chief Human Resources Officer,
since August 2011. From August 2008 to March 2011, Ms. Carmichael served as
Senior Vice President, Global Human Resources at Watson Pharmaceuticals, Inc.,
where she established and executed global HR strategies. From December 2005
to August 2008, Ms. Carmichael held various human resources positions of increasing
responsibility at Schering-Plough Corporation, including Vice President of Global
Human Resources at the Schering-Plough Research Institute. From December 2003
to December 2005, Ms. Carmichael was Vice President of Human Resources at Eyetech
Pharmaceuticals, Inc. Prior to Eyetech, she held various positions of increasing
responsibility in human resources at Pharmacia Corporation. Ms. Carmichael received
a B.A. in Psychology from Rider University.
John B. Moriarty, J.D. has been Senior Vice President and General Counsel since
December 2012. From December 2010 to December 2012, Mr. Moriarty served as General
Counsel and Chief Legal Officer at Elan Corporation plc, an Irish public limited
company traded on the New York and Irish Stock Exchanges, and also served as
a member of Elans Executive Management team. Prior to assuming the role of
General Counsel, Mr. Moriarty served as Senior Vice President of Law, Litigation
and Commercial Operations at Elan from December 2008 to December 2010. From
2002 to 2008, Mr. Moriarty held various positions with Amgen, Inc., including
Executive Director and Associate General Counsel, Global Commercial Operations
- Amgen Oncology and Senior Counsel, Complex Litigation, Products Liability
and Government Investigations. Between 1994 and 2002, Mr. Moriarty served in
various capacities in private practice focused on healthcare and as a healthcare
fraud prosecutor in the U.S. Attorneys Office and the Virginia Attorney Generals
Office. Mr. Moriarty received his J.D., cum laude, from the University of Georgia
School of Law and his B.A., with distinction, from the University of Virginia.
Frank J. Wright has been Senior Vice President and President of Alexion Pharma
International Sàrl since January 2013. Before joining Alexion, from August
2011 to February 2012, Mr. Wright served as Interim President of the Clinical
Trials Distribution Unit at Marken Limited, a global clinical supply chain solutions
provider. Mr. Wright co-founded Aptuit LLC in 2004, a provider of integrated
drug discovery and development services, and from 2004 to 2010 served as its
Vice Chairman and Chief Operating Officer. From 2000 to 2004, he was an independent
consultant advising pharmaceutical and biotechnology companies and private equity
firms with respect to acquisitions, asset valuation and emerging markets. From
1994 to 2000, Mr. Wright held various positions of increasing responsibility
at ChiRex, Inc., a Nasdaq-listed services company providing process research
and development and contract manufacturing services, acquired by Rhodia Pharma
in 2000, including as Co-Chief Executive Officer and Chief Operating Officer.
Prior to joining ChiRex, Mr. Wright served at Glaxo for 15 years in various
operational management, outsourcing and procurement positions. Mr. Wright studied
Mechanical Engineering at the University of Strathclyde, Glasgow.
Alexion Pharmaceuticals Inc currently has 3837 employees.
